CytoDyn (STU:296) Interest Expense: €-2.56 Mil (TTM As of Feb. 2026)


STU:296 CytoDyn Inc STU:296
27 GF Score
Price €0.21
! 1 Warning Sign
View Full Analysis

What is CytoDyn Interest Expense?

CytoDyn STU:296 +9.38% 27 Interest Expense is €-2.56 Mil as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CytoDyn's interest expense for the three months ended in Feb. 2026 was € -0.52 Mil. Its interest expense for the trailing twelve months (TTM) ended in Feb. 2026 was €-2.56 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CytoDyn's Operating Income for the three months ended in Feb. 2026 was € -5.33 Mil. CytoDyn's Interest Expense for the three months ended in Feb. 2026 was € -0.52 Mil. CytoDyn did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CytoDyn  (STU:296) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CytoDyn's Interest Expense for the three months ended in Feb. 2026 was €-0.52 Mil. Its Operating Income for the three months ended in Feb. 2026 was €-5.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Feb. 2026 was €23.01 Mil.

CytoDyn's Interest Coverage for the quarter that ended in Feb. 2026 is calculated as

CytoDyn did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

CytoDyn Interest Expense Historical Data

* Premium members only.

The historical data trend for CytoDyn's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Interest Expense Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.23 -14.25 -6.21 -5.31 -4.29

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.20 -0.90 -0.58 -0.56 -0.52
STU:296
27GF Score
CytoDyn Inc STU:296
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-2.56 Mil mean?
CytoDyn (STU:296) has a Interest Expense of €-2.56 Mil as of Feb. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on CytoDyn and its competitors.
Is CytoDyn's Interest Expense too high?
CytoDyn's current Interest Expense is €-2.56 Mil. Overall, CytoDyn has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Interest Expense compare to VSTM and IRD?
CytoDyn's Interest Expense of €-2.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on CytoDyn and its competitors. CytoDyn's current Interest Expense is €-2.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Interest Expense of €-2.56 Mil. The current Interest Expense is €-2.56 Mil. CytoDyn's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For CytoDyn (STU:296), the current Interest Expense is €-2.56 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
27GF Score

Get the complete analysis for STU:296

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price